Lowering the cost of treatments

The US FDA has approved SIMLANDI – a biosimilar to (and less costly than) Humira for the treatment of adult rheumatoid arthritis and many other autoimmune diseases including IBD. SIMLANDI is a product of the partnership between Israel’s Teva and the multinational Alvotech.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *